Biotech Values

[DewDiligence]

AVIR—If an antiviral drug can't reduce viral load better than placebo, you have a problem, but CEO Jean-Pierre Sommadossi actually said on today's CC that the clinical results were "as expected."

AVIR is already dosing AT-527 at a whopping 2200mg/day (1100mg BID), and the FDA won't let AVIR go higher because of toxicity with a chemically similar HCV drug that BMY discontinued in 2012 (#msg-78868766). I see no possible path for the AT-527 program to be resuscitated.